GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Debt-to-Equity

Shanghai Henlius Biotech (HKSE:02696) Debt-to-Equity : 1.57 (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Debt-to-Equity?

Shanghai Henlius Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$3,055 Mil. Shanghai Henlius Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$1,309 Mil. Shanghai Henlius Biotech's Total Stockholders Equity for the quarter that ended in Jun. 2024 was HK$2,776 Mil. Shanghai Henlius Biotech's debt to equity for the quarter that ended in Jun. 2024 was 1.57.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Shanghai Henlius Biotech's Debt-to-Equity or its related term are showing as below:

HKSE:02696' s Debt-to-Equity Range Over the Past 10 Years
Min: -9.47   Med: 0.91   Max: 2.25
Current: 1.57

During the past 7 years, the highest Debt-to-Equity Ratio of Shanghai Henlius Biotech was 2.25. The lowest was -9.47. And the median was 0.91.

HKSE:02696's Debt-to-Equity is ranked worse than
92.16% of 1021 companies
in the Biotechnology industry
Industry Median: 0.15 vs HKSE:02696: 1.57

Shanghai Henlius Biotech Debt-to-Equity Historical Data

The historical data trend for Shanghai Henlius Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech Debt-to-Equity Chart

Shanghai Henlius Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial 0.15 0.57 1.14 2.25 1.87

Shanghai Henlius Biotech Quarterly Data
Dec17 Mar18 Jun18 Dec18 Mar19 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.25 2.08 1.98 1.87 1.57

Competitive Comparison of Shanghai Henlius Biotech's Debt-to-Equity

For the Biotechnology subindustry, Shanghai Henlius Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Henlius Biotech's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Shanghai Henlius Biotech's Debt-to-Equity falls into.



Shanghai Henlius Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Shanghai Henlius Biotech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Shanghai Henlius Biotech's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Henlius Biotech  (HKSE:02696) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Shanghai Henlius Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Henlius Biotech Business Description

Traded in Other Exchanges
N/A
Address
B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
Executives
Ubs Group Ag
Golden Valley Value Select Master Fund 2101 Beneficial owner
Vistra Trust (singapore) Pte. Limited 2301 Trustee
Lvc Sg Management Pte. Ltd. 2201 Interest of corporation controlled by you
Lvc Management Holdings Limited 2201 Interest of corporation controlled by you
Lin Lijun 2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd. 2201 Interest of corporation controlled by you
Shanghai Fosun Pharmaceutical (group) Co., Ltd. 2201 Interest of corporation controlled by you
Guo Guangchang 2201 Interest of corporation controlled by you
Fosun International Limited 2201 Interest of corporation controlled by you
Fosun International Holdings Ltd. 2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited 2101 Beneficial owner
Fosun Holdings Limited 2201 Interest of corporation controlled by you
Qatar Investment Authority 2201 Interest of corporation controlled by you
Liu Scott Shi-kau 2201 Interest of corporation controlled by you

Shanghai Henlius Biotech Headlines

No Headlines